In Europe, plant-derived products are playing an increasingly prominent role in debates on health, regulation, and responsible consumption. Between CBD oils, hemp extracts, herbal preparations, and new cannabinoids, the market is evolving rapidly, while European authorities are seeking to better regulate the safety, quality, and distribution of these products. For adult consumers, this environment may seem complex, but it addresses a simple challenge: to better protect the public while improving the clarity of the available options.
In this context, three issues constantly intersect: access to healthcare, European standards, and traceability. These dimensions concern patients as much as consumers of wellness products, healthcare professionals, manufacturers, and distributors. Taking stock of plant-derived productstherefore means understanding how the European Union attempts to balance innovation, health precautions, and market transparency.
A rapidly changing European landscape
The European market for cannabis-derived products, and more broadly for plant-based products, has become increasingly complex. According to EUDA, by 2026, the emergence of products containing low levels of THC, CBD, or a combination of both is blurring traditional categories. The wellness, consumer, and public health response markets are now intertwined, making analysis more challenging for both authorities and consumers.
This evolution is accompanied by another phenomenon: the rapid diversification of formats. Flowers, resins, oils, capsules, CO₂ extracts, e-liquids, and products enriched with so-called next-generation cannabinoids coexist within a regulatory framework that is not uniform across uses and countries. The 2026 European Drug Report also highlights that this environment sometimes includes counterfeit or insufficiently documented products, hence the importance of verifying compliance and analyses before purchase.
For adult consumers in France and Europe, this shift creates both opportunities and areas of uncertainty. The range of products is expanding, prices are diversifying, and quality is improving among reputable players, but transparency increasingly depends on traceability, laboratory results, and brands' ability to clearly explain what they are selling. In such a dynamic sector, trust can no longer rely on marketing alone.
Access to healthcare: between real needs and still unequal pathways
The issue of access to healthcare remains central to the European debate. The European Commission reiterates that EU citizens can access healthcare in another Member State, with reimbursement in accordance with Directive 2011/24/EU. This right clearly demonstrates that cross-border access is an integral part of the European healthcare landscape, particularly when local services are insufficient or overly specialized.
But in reality, inequalities persist. European institutions still identify financial, cultural, and physical barriers that hinder access to care. This also applies to pathways related to certain herbal preparations or cannabis-derived products, particularly when it involves specialists, hospital facilities, or experimental programs. EUDA also notes that referrals to specialized care remain difficult in several drug-related areas.
This situation has concrete consequences. When access to medical information or appropriate support is limited, some consumers may turn to the market without sufficient guidance on uses, precautions, or potential interactions. Hence the importance of a clear framework that clearly distinguishes between wellness products, food items, plant extracts, and medications, in order to avoid confusion and better guide each individual according to their actual needs.
CBD in light of European food safety standards
In 2026, the EFSA further increased the level of scrutiny surrounding cannabidiol. On February 9, 2026, the authority set a provisional safety limit for CBD as a novel food at 0.0275 mg/kg of body weight per day, or approximately 2 mg per day for a 70 kg adult. This provisional limit comes with a very clear message: data gaps remain, particularly concerning the liver, as well as the endocrine, nervous, and reproductive systems.
The EFSA also specifies that the safety of CBD cannot be established for certain groups. These include those under 25, pregnant or breastfeeding women, and people undergoing medical treatment. For a reputable player in the sector, this implies responsible communication, avoiding trivialization or excessive promises, and clearly reminding users of the precautions for use.
It is also important to remember that the European Commission explicitly treats CBD as a novel food when it falls under the scope of novel food legislation. The opinion published by EFSA on March 30, 2026, on a CO₂ extract of Cannabis sativa L., confirms the extent to which plant-derived extracts remain subject to risk assessment prior to being placed on the market. For consumers, this means that an attractive product is not automatically compliant or adequately assessed.
Herbal medicines: the structuring role of the EMA and the HMPC
Beyond CBD as a consumer ingredient, Europe continues to structure the framework for herbal medicines. In 2026, the HMPC, the EMA's committee dedicated to herbal medicines, continued its work through meetings held in January, March, and May. These discussions focused in particular on monographs, guidelines, and the overall evolution of standards applicable to herbal preparations.
The HMPC remains strongly focused on quality. The EMA emphasizes its cooperation with the European Directorate for the Quality of Medicines and Healthcare on European Pharmacopoeia standards and quality guidance. In practice, this helps to regulate the composition, purity, botanical identification, and control methods of plant substances used in medicinal applications.
This distinction is important for the public. Not all plant-derived products are subject to the same level of requirements or have the same purpose. CBD oil marketed as a consumer product is not a medicine, whereas a plant-based preparation marketed under a pharmaceutical framework is subject to specific regulations. Understanding this difference helps to better interpret claims, avoid confusion, and choose a product that aligns with its intended use.
Traceability: the key to trust throughout the entire chain
Traceability has become an essential pillar of the sector. Within the European framework, the Commission defines food traceability according to the principle of “one step back, one step forward.” In practical terms, each operator must be able to identify, at a minimum, their immediate supplier and their immediate customer. This principle applies to the movement of foodstuffs, ingredients, and numerous raw materials throughout production, processing, and distribution.
For plant-derived products, this requirement is particularly useful. It allows for tracing the origin of a batch, verifying the path taken by a raw material, linking a finished product to laboratory analyses, and, if necessary, quickly withdrawing a problematic item from the market. The Commission rightly emphasizes that these rules strengthen cooperation between authorities and operators, while also improving transparency for the public.
For a reputable online store, traceability is not just an administrative detail. It's a tangible indicator of quality. Knowing the origin of the hemp, the controls implemented, how batches are tracked, and the corresponding analytical results makes a real difference. For adult consumers, this reduces the risk of unpleasant surprises and allows them to prioritize tested, legal, and well-documented products.
From field to finished product: plant controls and batch identification
Traceability begins well before products reach the shelves. European Union phytosanitary regulations require plant passports for certain plants and plant products, following inspections. These plant passports are part of the EU's plant health policy and aim to limit the spread of harmful organisms in intra-European trade. While not all finished products fall under exactly the same regulations, this approach demonstrates that plant origin remains a subject of close monitoring.
As the supply chain becomes more complex, the precise identification of products also gains importance. In January 2026, the EMA published an implementation guide mentioning IDMP/ISO standards to facilitate access to product information. This work primarily concerns the pharmaceutical sector, but it illustrates a fundamental trend: better structuring of data, better linking of product identifiers, and making information more usable by regulatory authorities and digital systems.
This dynamic aligns with the EMA's work on medicinal plant usage data, referencing electronic health records, national registries, and the European Health Data Space. Ultimately, improved data quality can help to more accurately document herbal preparations, their uses, and their safety profiles. For the sector, this paves the way for greater rigor, but also for better recognition of truly well-characterized products.
Between national frameworks and European supervision
The European Union sets principles, but member states retain significant leeway in the practical implementation of certain measures. The French example of medical cannabis is telling: a 2026 TRIS notification reiterates the strict framework for national experimentation, reserved for a last-line treatment and subject to close supervision. This demonstrates that cannabis-derived products can be subject to very different approaches depending on whether they are considered as food, wellness products, controlled substances, or regulated treatments.
This national diversity can be confusing for European consumers, especially in an online marketplace where product information circulates rapidly and purchasing habits often cross borders. A product tolerated in one country may not have the same status elsewhere, and thresholds, permitted forms, and documentation requirements can vary. For professionals, this necessitates constant regulatory monitoring and great care in product presentation.
In this context, legal compliance should never be assumed; it must be demonstrated. This is why the most reliable players emphasize independent analyses, clear information on composition, accurate product sheets, and customer service capable of explaining the applicable regulations. As the market diversifies, education becomes increasingly essential for building trust.
Towards a more mature, more transparent and more responsible market
The WHO's 2024 Global Traditional Medicines Report shows that access to herbal products, their governance, financing, and integration into healthcare systems are being monitored more closely worldwide. This foundation should inform the 2025-2034 strategy, demonstrating that medicinal plants and their derivatives are no longer a peripheral issue. They are now part of a broader discussion on access to care, quality, and public health.
At the same time, EUDA points out that the increasing availability of more varied and sometimes more potent products raises health risks and complicates treatment. In other words, market growth cannot be separated from increased responsibility on the part of sellers, manufacturers, and authorities. In an environment where CBD, low THC levels, new cannabinoids, and plant extracts coexist, reliable information is just as important as the product itself.
For adult consumers, the right approach remains simple: prioritize derived products plant- whose origin, composition, and analyses are clearly accessible. A competitive offering can perfectly well maintain high quality standards, provided that each product is supported by evidence, not just promises. This is where the maturity of the European sector lies: in its ability to make the market more transparent, more traceable, and safer.
The European situation presents a nuanced reality. On the one hand, access to herbal healthcare and products is progressing in institutional discussions, monitoring frameworks, and data tools. On the other hand, regulations are becoming stricter, safety assessments remain cautious, and inequalities in access persist. -derived products Plant thus lie at the intersection of several sectors: agriculture, food, well-being, pharmaceuticals, and public health.
To move forward smoothly, the course is clear: greater compliance, greater traceability, and greater education. In a dynamic market, adult consumers have every reason to choose transparent companies capable of documenting their products and respecting European regulations. This requirement is what makes it possible to reconcile accessibility, safety, and lasting trust.
